Related Experiment Video
Updated: Jul 24, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Infliximab-Induced Pneumonitis in a Patient With Sarcoidosis: A Case Report
Alexander Ali Jiménez Romero1, Mercedes Guillamón Sánchez1, María Del Carmen Velasco Alcazar1
1Department of Pneumology Hospital General Universitario Santa Lucía, Cartagena, Spain.
Infliximab, a tumor necrosis factor alpha (TNF-α) inhibitor, can cause rare lung toxicity. This case highlights infliximab-induced pneumonitis in pulmonary sarcoidosis, a condition requiring prompt diagnosis and treatment.
Area of Science:
- Pulmonology
- Rheumatology
- Immunology
Background:
- Infliximab (a TNF-α inhibitor) is used for pulmonary sarcoidosis.
- Infectious complications are known side effects.
- Non-infectious pulmonary toxicity is less commonly reported.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Pneumothorax-II
Clinical Manifestations:
Atypical Pneumonia
Pneumonia I: Introduction

